August 31, 2009
"For all the political risks of acting, 'Everyone knows the alternative is worse,' said Rahm Emanuel, Mr. Obama’s chief of staff and a veteran of the Clinton White House. 'Failure leads to failure.'"
Read more in New York Times, August 30, 2009.
Read more in POZ, August 31, 2009.
August 30, 2009
Read more in AIDS.gov, August 28, 2009.
August 29, 2009
Due to increased demand in certain medications, AID FOR AIDS International is in greater need of the following medication:
· Aptivus 250mg
· Atripla 600/300/200mg
· Emtriva 200mg
· Epivir 300mg
· Insentress 400mg
· Norvir 100mg
· Prezista 300mg
· Prezista 600mg
· Prezista 400mg
· Retrovir 300mg (Zidovudine 300mg)
· Truvada 300/200mg
· Videx 400mg EC (Didanosine 400mg)
· Viread 300mg
· Zerit 30mg
Special temporary request:
· Emend 80mg
· Metotrexate 40mg
If you or someone you know has excess of these or any other antiretroviral, please click here.
If you want to know where you can drop the medicine off, click here." [Note the mailing instructions, if you are not in the New York metropolitan area, or near the other drop-off points.]
Read more in AIDS for AIDS International, August 2009.
August 28, 2009
Read more in Retrovirology, August 27, 2009.
Comment: This technical article could be important. Both siRNA and shRNA are fairly new techniques for turning off a particular gene -- in this case for research, and potentially some day for treatment.
Read more in Aidsmap, August 27, 2009.
Comment: This study was in the UK, but the U.S. situation is probably similar, especially in regard to health at work. Discrimination may be more different between the countries.
August 27, 2009
Read more in POZ, August 25, 2009.
Read more in Aidsmap, August 25, 2009.
Read more in Aidsmap, August 25, 2009.
August 26, 2009
HVTN 505 is planned to take place in 12 U.S. cities and is designed to enroll 1,350 HIV-negative men ages 18 to 45 years who have sex with men. Participants must be circumcised and at the time they are enrolling, without Ad5 antibodies resulting from previous exposure to the Ad5 virus. ...
For more information about the HVTN 505 study, see Questions and Answers: The HVTN 505 HIV Vaccine Regimen Study and www.hopetakesaction.org."
Read more in U.S. NIAID, August 24, 2009.
August 25, 2009
This morning, AIDS.gov Director Miguel Gomezpresented on the plenary panel, “Advances in HIV Prevention Science and Technology.” The AIDS.gov presentation focused on how the HIV community can adopt new media tools to further their work. Miguel said, “we have a responsibility to learn about new media—to learn what clients are doing online, what new media is, and how to fit it into our overall HIV prevention planning.”
Note: Even if you have never used Twitter and do not have an account, you can click of the Twitter "hashtag" above to read recent "tweets" tagged for this conference.
"The decision by the health minister, Dr. Aaron Motsoaledi, to embrace the often withering assessment of his party’s failings, laid out in six papers published online Monday by The Lancet, a medical journal based in London, provided a strong signal that the governing party’s new leadership intended to shake up a badly managed health system."
Read more in New York Times, August 24, 2009.
Note: These articles are available to anyone, but free Lancet registration is required. Or you can read an executive summary (PDF download) without registering.
Read more in POZ, August 24, 2009.
"Just over 6000 members chose the response: “I don’t believe I’m at risk.”
"Commenting on the results of the survey, Dr Olive Shisana, CEO of the Human Sciences Research Council, said: “Not believing that they are at risk is quite common ... in fact, in the last survey we did, about 50% of the people infected thought they were not at risk of HIV!"
Read more in The Times (South Africa), August 22, 2009.
August 23, 2009
Read more in New England Journal of Medicine, August 2-, 2009.
"Organizations such as Doctors Without Borders and Oxfam International -- an anti-poverty group -- said they had hoped President Obama would join them in the fight to make generic drugs available to combat disease in impoverished countries.
"But 'it appears that Obama appointees are continuing to work from the playbook of the last administration,' said Oxfam policy advisor Rohit Malpani. The British-based group had opposed President George W. Bush's trade policies as being detrimental to public health."
Read more in Los Angeles Times, August 20, 2009.
Read more in CDC NPIN, August 13, 2009.
August 21, 2009
"Ghostwriting, which involves using medical writers to produce articles that are then nominally authored by an academic not substantially involved in the writing process, has been condemned as an unacceptable practice by medical journals and editors. Nonetheless, the practice appears to persist and by placing all the documents for scrutiny in the public domain, the editors of PLoS Medicine hope that they will help guide the way to identifying reforms that will eventually stamp ghostwriting out. ...
"In an editorial that has been posted on the PLoS Medicine blog, Speaking of Medicine (http://speakingofmedicine.plos.org/2009/08/21/ghostwriting-documents-now-fully-available-on-plos-medicine-website/), the PLoS Medicine editors declare that this is "one of the most compelling expositions ever seen of the systematic manipulation and abuse of scholarly publishing by the pharmaceutical industry and its commercial partners in their attempt to influence the health care decisions of physicians and the general public." The editors go on to call for action to eradicate ghost-writing, including retraction of papers where ghostwriting or inappropriate involvement of medical writers is found, banning of authors found to have put their names to such papers from any subsequent publication in the journal, and rigorous investigation of such misconduct by the researchers' academic institutions."
Read more in EurekAlert!, August 21, 2009.
"They have found that diabetics deficient in vitamin D can't process cholesterol normally, so it builds up in their blood vessels, increasing the risk of heart attack and stroke. The new research has identified a mechanism linking low vitamin D levels to heart disease risk and may lead to ways to fix the problem, simply by increasing levels of vitamin D. ...
"Worldwide, approximately one billion people have insufficient vitamin D levels, and in women with type 2 diabetes, the likelihood of low vitamin D is about a third higher than in women of the same age who don't have diabetes.
"The skin manufactures vitamin D in response to ultraviolet light exposure. But in much of the United States, people don't make enough vitamin D during the winter — when the sun's rays are weaker and more time is spent indoors."
Read more in EurekAlert!, August 21, 2009.
"WASHINGTON – President Obama today announced the launch of the National HIV/AIDS Community Discussions, a series of events to be held across the country. These events, hosted by the White House Office of National AIDS Policy (ONAP) will offer the public a chance to provide input as the White House works to fulfill the President’s pledge to develop a National HIV/AIDS Strategy (NHAS). The first event, the Atlanta HIV/AIDS Community Discussion, will be held on August 25th at the 2009 National HIV Prevention Conference.
"HIV remains an serious challenge to the American people and I am committed to developing an effective National HIV/AIDS Strategy," said President Obama. "The National HIV/AIDS Community Discussions will provide an opportunity for members of the public to give their input on how we can best address this crucial issue. With the insights from communities across the country, we will have a strategy that is focused on the goals of reducing HIV incidence, getting people living with HIV/AIDS into care and improving health outcomes, and reducing HIV-related health disparities."
Read more in The White House, August 21, 2009.
Read more in Health Day - U.S. News and World Report, August 12, 2009.
August 20, 2009
"HIV is the sixth leading cause of death among 25 to 44 year olds," New York Times' Well blog reports (Parker-Pope, 8/19). According to the report, "[a]lthough Human immunodeficiency virus (HIV) disease was not one of the 15 leading causes of death in 2007, it is still of concern" (Xu et al., Deaths: Preliminary Death Data for 2007, 8/19)."
Read more in Kaiser Daily U.S. HIV/AIDS Report, August 20, 2009.
"For years, European countries like Switzerland and the Netherlands have allowed doctors to provide some addicts with prescription heroin as an alternative to buying drugs on the street. The treatment is safe and keeps addicts out of trouble, studies have found, but it is controversial — not only because the drug is illegal but also because policy makers worry that treating with heroin may exacerbate the habit."
Read more in New York Times, August 19, 2009.
Obesity and diabetes main underlying health conditions in people dying of swine flu: no evidence that HIV increases mortality risk
"The authors from the French Institute of Public Health analysed all deaths caused by swine flu before 16th July."
Read more in Aidsmap, August 20, 2009.
August 18, 2009
Read more in Treatment Education Expansion Project, August 2009.
Note: this survey of healthcare nightmares by the AIDS Foundation of Chicago has only 3 questions.
"Participation Powers Prevention": Highlights from CDC's 3rd National Conference on Health Communication, Marketing, and Media
"We wanted to bring some of the key messages from the conference to people who couldn't be there in person, so we used our Flip camera to record interviews with several speakers and participants about their advice for the HIV community."
Read more in AIDS.gov Blog, August 18, 2009.
Activation of Latent HIV Type 1 Gene Expression by Suberoylanilide Hydroxamic Acid (SAHA), an HDAC Inhibitor Approved for Use to Treat Cutaneous T...
Read more in AIDS Research and Human Retroviruses, August 18, 2009.
August 17, 2009
The 14th International Conference on Human Retrovirology: HTLV and related retroviruses (July 1-4, 2009; Salvador, Brazil)
Read more in Retrovirology, August 17, 2009.
Note: This publication focuses not on HIV, but on HTLV, a different retrovirus that infects about 15-20 million people worldwide. The full text of a provisional PDF draft is available to anyone at this time.
"Furthermore, the investigators found that the gene was more strongly associated with response to treatment in European-Americans than either baseline hepatitis C viral load or liver fibrosis, the usual predictors of hepatitis C treatment response.
"However, in African-Americans and Hispanics, both of these traditional risk factors were a better guide to treatment response than the presence of the gene."
Read more in Aidsmap, August 17, 2009.
Comment: This problem is likely to be more severe in the U.S. than in Canada.
Read more in JAIDS, August 13, 2009.
The Acute Effects of HIV Protease Inhibitors on Insulin Suppression of Glucose Production in Healthy HIV-Negative Men
Read more in JAIDS, August 14, 2009.
August 16, 2009
Treat Early or Wait and Monitor? A Qualitative Analysis of Provider Hepatitis C Virus Treatment Decision-Making in the Context of HIV Coinfection
Read more in AIDS Patient Care, August 10, 2009.
August 14, 2009
Read more in Aidsmap, August 13, 2009.
A Systematic Review of Permanent and Semipermanent Dermal Fillers for HIV-Associated Facial Lipoatrophy
Read more in AIDS Patient Care and STDs, August12 , 2009.
Read more in Reuters, August12 , 2009.
Aids Activists Rally This Sunday To Support Lifting U.S. Ban On HIV-Positive Immigrants And Visitors
Read more in positivelypositive.ca, August 16 (rally), 2009.
Comment: The main rally is in Canada, near Buffalo, NY. The website has contacts for information about other locations.
August 11, 2009
"The rates of some non-AIDS-related malignancies, particularly anal cancer, are higher in people with HIV than in their HIV-negative counterparts. What’s more, the number of people with HIV diagnosed with anal cancer each year has grown, rather than decreased, since the introduction of potent antiretroviral therapy."
Read more in POZ, August 10, 2009.
The global maternal mortality ratio of 400 per 100,000 live births as estimated by the World Health Organization does not reveal the considerable regional variations.
In 2005, South Africa—a middle income country—had a ratio close to the global average but considerably higher than countries of similar gross domestic product per person, for example, Portugal and Brazil which had a ratio of 11 and 110 respectively. "
Read more in Aidsmap, August 10, 2009.
August 8, 2009
"With immediate effect the drugs —tenofovir, lamivudine (3TC), atazanavir and a boosting dose of ritonavir—will be available at a price of $475. That’s $115 less than the previous cheapest option for second-line treatment, lopinavir/ritonavir plus tenofovir/3TC, currently being offered to qualifying countries in the developing world by the Clinton HIV/AIDS Initiative Procurement Consortium at a ceiling price of $590 a year. "
Read more in Aidsmap, August 6, 2009.
Read more in Chicago Free Press, August 6, 2009.
Comment: This appears to be a legitimate dispute with understandable reasons on both sides. Our first impression would be to side with GeoVax and do the trial.
Read more in POZ, August 7, 2009.
Note: See abstract of Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir.
August 7, 2009
"Though the drugs they found aren’t at all ready for human testing, the work of Shahian, Craik and their colleagues could pave the way for drug development that could substantially move the treatment of all herpes viruses a huge leap forward."
Read more in POZ, August 4, 2009.
August 4, 2009
"In the book you compare AIDS denialism to a beehive. Could you explain that?
"What I was trying to convey is that if you take a look at all the different denialist websites and the blogs and the magazine articles, a lot of it looks fairly chaotic from a distance. You’ve got people saying HIV doesn’t even exist and no one can prove it. Then you’ve got Peter Duesberg who’s saying HIV does exist but it’s harmless. Then you’ve got other people who say HIV isn’t harmless, but it’s not sexually transmitted. And from a distance it looks like it’s a very uncoordinated, sort of swarm. Like a beehive does from a distance. But as you get closer, you see that it’s very well organized. And actually there is a centralized group, and it is the Rethinking AIDS group. And there are three or four people who are very involved in that.
"To write this book I actually went undercover. I never misrepresented myself. I posed as a student of public health, which of course I am. But I had to be able to talk to these guys without barriers. I wanted to get to know what was really going on with them. And as I did that, I saw they’re very well connected with each other. In fact, there’s a vetting process that I went through to be listed as an AIDS dissident on the Rethinking AIDS website. Christine Maggiore herself vetted me, and I was posted. And once I was listed on there, the door was open to me. They would all talk to me. And it was actually very well organized. And, in that way, like a beehive.
"And the other part of the swarm thing is, I do expect to get stung by this. The hate mail has already started. The online assault has started—which I fully expect. For the book to be successful, they’ve got to come after me. If they don’t then I think the book was probably a waste of time.
"What do you hope readers take away from the book?
"I hope there’s a couple things that they take away. One thing I hope they take away is that they can’t believe everything they read online and in books. They really need to think critically about the information that they’re getting; they need to think hard about the doctor they are seeing and be really good consumers of health care. Not to be close-minded, but be critically thinking. If a new idea comes out or if they hear something different that their doctor didn’t tell them, they should listen and attend to it.
"One thing I really hope that folks with HIV will look at carefully is the credibility of who’s saying what they’re listening to. Not the credentials, but the credibility. You have professors saying HIV doesn’t cause AIDS and that you don’t have to worry about it. And those same professors say that the Loch Ness Monster exists. That should mean something.
"That’s something that I’d hope the readers of POZ walk away with. That they really have a role in combating this misinformation. They have a role to become informed and to not be silent when they see misinformation. If they see something on a blog that they know to be garbage, comment on it. People who are buying into it are very vocal and very visible. And everyone else is ignoring them. So it looks like everybody’s buying into this.
"All royalties from Denying AIDS will help the Family Treatment Fund provide antiretroviral medication for people living with HIV/AIDS in Africa."
Read more in POZ, August 3, 2009.
Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection
Read more in JAIDS, August 3 , 2009.
August 3, 2009
Are We Meeting the American Diabetes Association Goals for HIV‐Infected Patients with Diabetes Mellitus?
Read a little more in Clinical Infectious Diseases, July 27, 2009.
Scientists have uncovered details of an immune-cell environment conducive to HIV infection that persists at the location of HSV-2 genital skin lesions long after they have been treated with oral doses of the drug acyclovir and have healed and the skin appears normal. These findings are published in the advance online edition of Nature Medicine on Aug. 2."
Read more in NIAID news release, August 2, 2009.
Acetylcholine-Esterase Inhibitor Pyridostigmine Decreases T Cell Overactivation in Patients Infected by HIV
Read more in AIDS Research and Human Retroviruses, online August 1, 2009.
Comment: This early human study could be important. The drug is approved but hazardous; it may have caused Gulf War Syndrome in the 1991 war, when it was used as protection against possible nerve-gas attack.
August 1, 2009
Read more in Project Inform, August 1 , 2009.